Company news
Immutep Ltd (ASX:IMM) news
Immutep Ltd news releases on 6ix. Latest, Oct 30, 2020: Immutep enters into a Licence & Collaboration with LabCorp
Press releases — page 5
Immutep enters into a Licence & Collaboration with LabCorp
October 29, 2020
2020 AGM Presentation
October 26, 2020
COVID-19 phase 2 investigator initiated trial commences
October 22, 2020
Immutep granted European patent for IMP761
October 21, 2020
Immutep reports improving results from INSIGHT-004 trial
September 17, 2020
IMM & Monash Uni receive funding grant for LAG-3 Research
August 30, 2020
Appendix 4E & 2020 Full Year Statutory Accounts
August 25, 2020
Recruitment of stage 1 of part B in TACTI-002 study complete
August 17, 2020
Immutep granted US patent for eftilagimod alpha
August 11, 2020
US patent granted for IMP701 antibody
July 14, 2020
Immutep Completes Recruitment for Part A of TACTI-002 trial
June 28, 2020
Immutep receives A$1,437,826 R&D Tax Incentive
June 21, 2020
Immutep announces improving data from TACTI-002 ph II trial
May 31, 2020
Immutep receives $3.6M R&D French tax incentive
May 28, 2020
Immutep granted Japanese patent for eftilagimod alpha
May 6, 2020
INSIGHT-004 and TACTI-002 data to be presented at ASCO
April 29, 2020
Immutep Investor Presentation
April 28, 2020
Immutep Reports Positive Phase II TACTI-002 Data
April 27, 2020
Enrollment completed for the INSIGHT-004 Study
April 21, 2020
Immutep March Quarterly Activities Report & Appendix 4C
April 20, 2020
Immutep advances its LAG-3 agonist for autoimmune diseases
April 15, 2020
Immutep presents TACTI-002 data at AACR Virtual Meeting
April 14, 2020
EOC Pharma confirms plans to advance Efti in China for MBC
April 8, 2020
Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides
March 25, 2020
Immutep reports supportive efficacy data from AIPAC study
March 24, 2020
Immutep receives 2nd IND approval for efti from US FDA
March 8, 2020
Immutep reports positive TACTI-002 data
February 18, 2020
Immutep Activities Report
January 28, 2020
Immutep expands Part C of TACTI-002 due to positive data
January 8, 2020
INSIGHT-004 clinical trial update
December 18, 2019
Immutep announces European patent grant for LAG525 antibody
November 13, 2019
Appendix 4C - quarterly
October 23, 2019
Immutep presents positive TACTI-mel melanoma trial data
October 14, 2019
Immutep receives A$2.5M R&D French Tax Incentive
October 9, 2019
Immutep expands Part A of TACTI-002 due to positive data
September 25, 2019
Immutep to receive GBP4M Milestone Payment from GSK
September 22, 2019
Japanese patent granted for LAG525 antibody
September 16, 2019
Immutep granted European patent for IMP321 in cancer
August 21, 2019
Appendix 4E & 2019 Full Year Statutory Accounts
August 20, 2019
Entitlement Offer Results & Shortfall Notification
August 1, 2019
Immutep Entitlement Offer Booklet
July 8, 2019
Immutep completes recruitment of AIPAC trial in MBC
June 24, 2019
Immutep granted Australian patent for eftilagimod alpha
June 20, 2019
Immutep completes recruitment of initial NSCLC cohort
June 13, 2019
First patient dosed in INSIGHT-004
June 5, 2019
Immutep granted European patent for eftilagimod alpha
May 22, 2019
More mature positive data for TACTI-mel trial presented
May 16, 2019
Immutep granted US patent for IMP321
March 21, 2019
IMP761 results presented at ECCO conference
March 7, 2019
Immutep doses First Patient in TACTI-002 Phase II Trial
March 6, 2019